Related Experiment Video
Updated: Jul 4, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia
Gerald F Watts1,2, Laney K Jones3, Mitchell N Sarkies4
1School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Insights
Familial hypercholesterolaemia (FH) affects millions globally but remains underdiagnosed. The International Atherosclerosis Society (IAS) provides new guidance for FH detection, management, and implementation strategies to improve patient care.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Public Health
Background:
- Familial hypercholesterolaemia (FH) is a common, inherited disorder causing premature cardiovascular disease.
- Despite its prevalence, FH is often undetected and undertreated worldwide.
- Existing guidelines lack focus on implementation science for FH care.
Purpose of the Study:
- To present evidence-informed guidance from the International Atherosclerosis Society (IAS) for FH detection and management.
- To provide implementation strategies to optimize care models for FH patients.
- To address gaps in FH care through practical, actionable recommendations.
Main Methods:
- Guidance development based on evidence review.
- Partitioning guidance into detection, management, and implementation sections.
- Incorporating implementation strategies from the Expert Recommendations for Implementing Change taxonomy.
Main Results:
- Comprehensive guidance covers FH screening, diagnosis, genetic testing, risk stratification, and treatment for adults and children (heterozygous and homozygous).
- Includes management during pregnancy and use of lipoprotein apheresis.
- Offers specific and general implementation strategies, emphasizing health policy, multidisciplinary teams, training, patient-reported outcomes, and digital health.
Conclusions:
- The IAS guidance provides a framework for improving FH detection and management globally.
- Implementation strategies are crucial for adapting care to local needs and ensuring sustainable funding.
- Collaboration between healthcare providers, policymakers, and researchers is essential for advancing FH care.
Abstract:
Familial hypercholesterolaemia (FH), a common monogenic disorder, is a preventable cause of premature coronary artery disease and death. Up to 35 million people worldwide have FH, but most remain undetected and undertreated. Several clinical guidelines have addressed the gaps in care of FH, but little focus has been given to implementation science and practice. The International Atherosclerosis Society (IAS) has developed an evidence-informed guidance for the detection and management of patients with FH, supplemented with implementation strategies to optimize contextual models of care. The guidance is partitioned into detection, management and implementation sections. Detection deals with screening, diagnosis, genetic testing and counselling. Management includes risk stratification, treatment of adults and children with heterozygous and homozygous FH, management of FH during pregnancy, and use of lipoprotein apheresis. Specific and general implementation strategies, guided by processes specified by the Expert Recommendations for Implementing Change taxonomy, are provided. Core generic implementation strategies are given for improving care. Nation-specific cholesterol awareness campaigns should be utilized to promote better detection of FH. Integrated models of care should be underpinned by health policy and adapted to meet local, regional and national needs. Clinical centres of excellence are important for taking referrals from the community. General practitioners should work seamlessly with multidisciplinary teams. All health-care providers must receive training in essential skills for caring for patients and families with FH. Management should be supported by shared decision-making and service improvement driven by patient-reported outcomes. Improvements in services require sharing of existing resources that can support care. Advocacy should be utilized to ensure sustainable funding. Digital health technologies and clinical quality registries have special value. Finally, academic-service partnerships need to be developed to identify gaps in care and set priorities for research. This new IAS guidance on FH complements the recent World Heart Federation Cholesterol Roadmap.
More Related Videos
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
09:14The Rabbit Model of Accelerated Atherosclerosis: A Methodological Perspective of the Iliac Artery Balloon Injury
Published on: October 3, 2017
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...